Sooo quiet! Just 2 weeks left for July. What will we see? Will the biotech watchers load in in preparation for the Prur trial start? Will we see a run? Or will they hold off for the patent issuance? Maybe. The community as a whole can be kinda particular when it comes to patents on a drug that won't get a designated new chemical entity status with 3-5 year exclusivity protection. This is where we rely so heavily on good management. If they have indeed hired the best patent attorney around - then NCE means little and 20 years of patent protection means everything. Ctix happens to have Dr.Paul Ginsberg sitting on their board. Really? How on earth does such a small little early phase biotech get someone of that stature to be a board member and to do the oversight work of the Prurisol patent? Dr. Menon has some serious connections!

I think we're in good hands! Here is an FDA q&A re patents vs NCE. Worth a read. https://tinyurl.com/oxn24de

And later, when Kevetrin is going for approval, we will be watching this: https://tinyurl.com/yhr2tvf , the Orange Book, to confirm the number of years of exclusivity granted to this novel agent. Absolute best case scenario for NCE exclusivity is orphan drug status protection of 7 years. Combined with tight patent wrap, such exclusivity guarantees years of owning the market....